The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims Roots Analysis London, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings. Porphyria is a rare...

Innovative drug launched for rare, isolating, “light intolerance” disorder MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or...

US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPPNDA filing allowed on a rolling basisFDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment ...